Dr. Burgess is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
1021 Morehead Medical Drive
Suite 6100
Charlotte, NC 28204Phone+1 980-442-0410Fax+1 980-442-9341- Is this information wrong?
Education & Training
- Vanderbilt University Medical CenterFellowship, Hematology and Medical Oncology, 2004 - 2009
- Vanderbilt University Medical CenterResidency, Internal Medicine, 2002 - 2004
- Medical College of Georgia at Augusta UniversityClass of 2002
- Wake Forest UniversityB.S., Magna Cum Laude, 1997
Certifications & Licensure
- NC State Medical License 2009 - 2024
- SC State Medical License 2009 - 2015
- TN State Medical License 2004 - 2009
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Fellow ECCO-AACR-EORTC-ESMO Methods in Clinical Cancer Research, 2014
- Think Tank Member Bladder Cancer Advocacy Network, 2013
- Young Investigator Award American Society of Clinical Oncology, 2007
Clinical Trials
- LCI-GU-URO-CRI-001: Crizotinib in Patients With c-MET or RON-Positive Metastatic Urothelial Cancer Start of enrollment: 2016 Sep 27
- A Trial of Androgen Deprivation, Docetaxel, and Enzalutamide for Metastatic Prostate Cancer Start of enrollment: 2017 Aug 23
Publications & Presentations
PubMed
- RNA-Based Homologous Recombination Deficiency Signature Detects Homologous Recombination Deficiency-RNA+ Patients With and Without Homologous Recombination Repair Gene...Zhu, J., Mauer, E., Thiede, S., Macera, L., Stein, M., Taxter, T., Brown, L., Raghavan, D., Burgess, E.> ;JCO Precision Oncology. 2023 Sep 1
- 1 citationsCOVID-19 vaccine uptake trends in SARS-CoV-2 previously infected cancer patients.Zainab Shahid, Alicia L Patrick, Michelle L Wallander, Erin E Donahue, Sally J Trufan, Antoinette R Tan, Jimmy J Hwang, Earle F Burgess, Brittany Ragon, Nilanjan Ghosh...> ;Vaccine. 2023 Aug 1
- 12 citationsEnfortumab Vedotin With or Without Pembrolizumab in Cisplatin-Ineligible Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer.Peter H O'Donnell, Matthew I Milowsky, Daniel P Petrylak, Christopher J Hoimes, Thomas W Flaig, Nataliya Mar, Helen H Moon, Terence W Friedlander, Rana R McKay, Mehmet...> ;Journal of Clinical Oncology. 2023 Sep 1
- Join now to see all
Journal Articles
- Individualized Management of Advanced Bladder Cancer: Where Do We Stand?Burgess EF, Urologic Oncology, 1/1/2015
- Prostate Cancer: What Did We Learn from the 2012 Annual Tumors-What Have We Learned in 35 Years?Riggs S, Burgess EF, Gaston D, Raghavan D, Oncologist, 1/1/2014
- Prostate Cancer Serum Biomarker Discovery Through Proteomic Analysis of Alpha-2 Macroglobulin Protein ComplexesBurgess EF, Ham AL, Tabb DL et al, Proteomics-Clinical Applications, 1/1/2008
- Join now to see all
Books/Book Chapters
Abstracts/Posters
- Molecular profiles of small cell bladder and prostate cancer and comparisons with small cell lung cancer.Dawson N, Geynisman D, Burgess E, Somer B, Arguello D, Hauke R, Vaena D, Raghavan D, Heath E, J Clin Oncol, 1/1/2018
- Erdafitinib (ERDA; JNJ-42756493), a pan-fibroblast growth factor receptor inhibitor, in patients with metastatic or unresectable urothelial carcinoma and FGFR alterati...Loriot Y, Necchi A, Park S, Garcia-Donas J, Huddart R, Burgess E, Fleming M, Rezazadeh A, Mellado B, Varlamov S, Joshi M, Duran I, OHagan A, Avadhani A, Zhong B, Stuyc..., Clin Oncol, 1/1/2018
- Efficacy of programmed death 1 (PD-1) and programmed death 1 ligand (PD-L1) inhibitors in patients with FGFR mutations and gene fusions: Results from a data analysis o...Siefker-Radtke A, Necchi A, Rosenbaum E, Culine S, Burgess E, O'Donnell P, Tagawa S, Zakharia Y, OHagan A, Avadhani A, Zhong B, Santiago-Walker A, Roccia T, Loriot Y, J Clin Oncol, 1/1/2018
- Join now to see all
Press Mentions
- A Gene Signature-Based Approach Identifies mTOR as a Regulator of p73▿August 4th, 2020
- A Phase II Trial of Enzalutamide, Docetaxel and Androgen Deprivation Therapy (ENZADA) in Patients with mCSPCJune 4th, 2018
- ENZADA, A Phase II Trial of Enzalutamide, Docetaxel, and Androgen Deprivation in Patients with Metastatic Hormone Sensitive Prostate Cancer - Earle BurgessNovember 15th, 2018
Professional Memberships
- Member
Hospital Affiliations
- Atrium Health's Carolinas Medical CenterCharlotte, North Carolina
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: